Antonella Isacchi
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Novel Thienoduocarmycin-Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies.
Journal: Molecular cancer therapeutics
Published: May 23, 2023
Stereoselective synthesis of 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as PIM kinase inhibitors inspired from marine alkaloids.
Journal: Chirality
Published: May 14, 2022
A single-cell analysis of breast cancer cell lines to study tumour heterogeneity and drug response.
Journal: Nature communications
Published: June 01, 2021
Identification of unprecedented ATP-competitive choline kinase inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: April 27, 2021
Mining potentially actionable kinase gene fusions in cancer cell lines with the KuNG FU database.
Journal: Scientific data
Published: August 24, 2020
Correction to Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Journal: Journal of medicinal chemistry
Published: August 20, 2019
Molecular Dynamics Simulations of p97 Including Covalent, Allosteric and ATP-competitive Inhibitors.
Molecular Dynamics Simulations of p97 Including Covalent, Allosteric and ATP-competitive Inhibitors.
Journal: Acta chimica Slovenica
Published: June 01, 2019
A benchmarking of pipelines for detecting ncRNAs from RNA-Seq data.
Journal: Briefings in bioinformatics
Published: May 28, 2019
Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515.
Journal: ACS medicinal chemistry letters
Published: November 22, 2018
Comprehensive kinome NGS targeted expression profiling by KING-REX.
Journal: BMC genomics
Published: July 25, 2018
PATRI, a Genomics Data Integration Tool for Biomarker Discovery.
Journal: BioMed research international
Published: March 20, 2018
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
Journal: Investigational new drugs
Published: June 02, 2017
Last Updated: 09/26/2026